About Owens & Minor, Inc.
https://www.owens-minor.comOwens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally. It operates through two segments, Global Solutions and Global Products. The Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers.
CEO
Edward A. Pesicka
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2010-04-01 | Forward | 3:2 |
| 1994-06-09 | Forward | 3:2 |
ETFs Holding This Stock
Summary
Showing Top 3 of 48
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
COLISEUM CAPITAL MANAGEMENT, LLC
Shares:13.1M
Value:$35.11M
BLACKROCK INC.
Shares:11.6M
Value:$31.09M
VANGUARD GROUP INC
Shares:5.96M
Value:$15.98M
Summary
Showing Top 3 of 299
About Owens & Minor, Inc.
https://www.owens-minor.comOwens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally. It operates through two segments, Global Solutions and Global Products. The Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $697.26M ▲ | $295.73M ▼ | $-150.28M ▲ | -21.55% ▲ | $-1.94 ▲ | $89.49M ▲ |
| Q2-2025 | $681.92M ▼ | $364.31M ▼ | $-869.06M ▼ | -127.44% ▼ | $-11.3 ▼ | $459K ▼ |
| Q1-2025 | $2.63B ▼ | $525.89M ▼ | $-24.98M ▲ | -0.95% ▲ | $-0.32 ▲ | $60.04M ▲ |
| Q4-2024 | $2.7B ▲ | $841.73M ▲ | $-296.12M ▼ | -10.98% ▼ | $-3.84 ▼ | $-198.77M ▼ |
| Q3-2024 | $686.85M | $300.69M | $-12.77M | -1.86% | $-0.17 | $91.53M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $32.84M ▼ | $4.04B ▼ | $4.47B ▲ | $-429.51M ▼ |
| Q2-2025 | $38.26M ▼ | $4.15B ▼ | $4.44B ▲ | $-281.01M ▼ |
| Q1-2025 | $59.44M ▲ | $4.86B ▲ | $4.29B ▲ | $570.98M ▲ |
| Q4-2024 | $49.38M ▲ | $4.66B ▼ | $4.09B ▼ | $565.23M ▼ |
| Q3-2024 | $45.45M | $5.08B | $4.21B | $874.59M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-150.28M ▼ | $-172.52M ▼ | $-39.46M ▲ | $181.1M ▲ | $-30.92M ▼ | $-230.35M ▼ |
| Q2-2025 | $-83.82M ▼ | $37.61M ▲ | $-52.92M ▼ | $31.7M ▼ | $-21.18M ▼ | $-30.27M ▲ |
| Q1-2025 | $-24.98M ▲ | $-35.07M ▼ | $-48.2M ▲ | $92.78M ▲ | $10.05M ▲ | $-99.74M ▼ |
| Q4-2024 | $-296.12M ▼ | $71M ▲ | $-52.3M ▼ | $-43.1M ▲ | $-25.71M ▲ | $8.17M ▲ |
| Q3-2024 | $-12.77M | $27.31M | $-27.19M | $-199.59M | $-198.38M | $-34.21M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Diabetes Product | $0 ▲ | $0 ▲ | $190.00M ▲ | $200.00M ▲ |
 Patient Direct | $700.00M ▲ | $670.00M ▼ | $0 ▼ | $0 ▲ |
 Product and Service Other | $0 ▲ | $0 ▲ | $70.00M ▲ | $70.00M ▲ |
 Products Healthcare Services | $2.00Bn ▲ | $1.96Bn ▼ | $0 ▼ | $0 ▲ |
 Urology | $0 ▲ | $0 ▲ | $30.00M ▲ | $30.00M ▲ |
 Wound Care | $0 ▲ | $0 ▲ | $50.00M ▲ | $50.00M ▲ |
Revenue by Geography
| Region | Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 |
|---|---|---|---|---|
 NonUS | $60.00M ▲ | $60.00M ▲ | $60.00M ▲ | $50.00M ▼ |
 UNITED STATES | $2.61Bn ▲ | $2.66Bn ▲ | $2.64Bn ▼ | $2.58Bn ▼ |
CEO
Edward A. Pesicka
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2010-04-01 | Forward | 3:2 |
| 1994-06-09 | Forward | 3:2 |
ETFs Holding This Stock
Summary
Showing Top 3 of 48
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
COLISEUM CAPITAL MANAGEMENT, LLC
Shares:13.1M
Value:$35.11M
BLACKROCK INC.
Shares:11.6M
Value:$31.09M
VANGUARD GROUP INC
Shares:5.96M
Value:$15.98M
Summary
Showing Top 3 of 299